Canada Markets open in 8 hrs 16 mins

Advanced Proteome Therapeutics Corporation (APC.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1800+0.0650 (+56.52%)
At close: 03:59PM EDT
Full screen
Previous Close0.1150
Open0.1350
Bid0.1150 x 0
Ask0.1350 x 0
Day's Range0.1400 - 0.2100
52 Week Range0.0900 - 0.3500
Volume516,049
Avg. Volume21,074
Market Cap6.795M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry

    [DATELINE]Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), has had its technology featured in a peer-reviewed publication.The manuscript entitled, "Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates" by Sarrett, et al. has been published in the prestigious journal, Bioconjugate Chemistry. Bioconjugate Chemistry is a peer-rev

  • Newsfile

    Advanced Proteome Therapeutics Receives Issued Patent

    Vancouver, British Columbia--(Newsfile Corp. - August 3, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that the United States Patent and Trademark Office has issued a patent to its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").On August 2, 2022, APTI was issued U.S. Patent No. 11,400,165 titled 'Composition and method for modifying polypeptides'. The patent covers highly site-selective antibody conjugate c

  • Newsfile

    Advanced Proteome Therapeutics Receives Notice of Allowance for Patent Claims

    Vancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has received a notice of allowance for patent claims covering key intellectual property.APTI has been informed that the first set of claims from US patent application 16/180,960 have been allowed. These claims cover highly site-selective antibody conju